Noemi Reguart, Medical Oncologist at Hospital Clinic Barcelona, shared a post on X:
“The FDA has granted full approval to Imdelltra for extensive-stage SCLC, based on the Phase 3 DeLLphi-304 trial.
A major step forward for patients and clinicians. Looking forward to EMA’s evaluation.”
You can also read: Tarlatamab (Imdelltra): Uses in Cancer, Side Effects, Dosages, Expectations, and More
